CSF sphingomyelin: possible biomarker of demyelination
- PMID: 33361407
- DOI: 10.1136/jnnp-2020-324931
CSF sphingomyelin: possible biomarker of demyelination
Keywords: CSF; guillain-barre syndrome; myelin; neuroimmunology; neuropathy.
Conflict of interest statement
Competing interests: SK reports grants from the Ministry of Health, Labour and Welfare of Japan during the conduct of the study; grants from Teijin, grants from Japan Blood Product Organization; grants from Nihon Pharmaceutical; personal fees from Teijin, Japan Blood Product Organization, Nihon Pharmaceutical and CSL Behring, outside the submitted work.
Comment on
-
CSF sphingomyelin: a new biomarker of demyelination in the diagnosis and management of CIDP and GBS.J Neurol Neurosurg Psychiatry. 2021 Mar;92(3):303-310. doi: 10.1136/jnnp-2020-324445. Epub 2020 Oct 22. J Neurol Neurosurg Psychiatry. 2021. PMID: 33093191 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical